Periodic limb movement disorder: PLMS, PLMD, and restless legs syndrome

"Leg jerking at night" gets used loosely, but it points to at least three distinct things: restless legs syndrome (RLS) itself, periodic limb movements in sleep (PLMS) as a measurable sign, and periodic limb movement disorder (PLMD) as its own separate diagnosis. Telling them apart matters, because they are diagnosed differently and, in PLMD's case, treated somewhat differently.

Restless legs syndrome is diagnosed clinically, from symptoms alone — no blood test, brain scan, or sleep study is required. The updated international (IRLSSG) consensus criteria require all five of the following to be present.

Periodic limb movements in sleep (PLMS) are a different, objective thing: repetitive, brief leg (occasionally arm) movements picked up on an overnight sleep study. A movement rate above 15 per hour — the PLMS index — is the threshold commonly treated as clinically significant. In one large population-based sleep-study cohort, that threshold was crossed by 28.6% of adults (31.3% of men, 26% of women), and was also linked to the same genetic variants (BTBD9, TOX3, MEIS1) implicated in RLS.

Periodic limb movement disorder (PLMD) is the name for a third, more specific situation: significant PLMS that occurs on its own, causing disrupted sleep or daytime symptoms, without restless legs syndrome or another explanation (such as sleep apnea or a medication side effect) accounting for it. In practice, most people with RLS also have PLMS on a sleep study — but PLMS, and PLMD as its own diagnosis, can also occur in someone who does not have restless legs syndrome at all.

PLMS and PLMD are diagnosed with overnight polysomnography — a sleep study that records leg-muscle activity (via surface electrodes), brain waves, breathing, and heart rate through the night — not by a symptom questionnaire alone. A PLMS index above 15 movements per hour of sleep is the commonly used clinically-significant threshold.

That number is noisier than it looks, in two separate ways. First, both accepted scoring rule sets (AASM and WASM/IRLSSG) have been shown to over-count movements in people who also have obstructive sleep apnea, because a leg twitch right after a breathing event gets miscounted as an independent periodic limb movement: in one study, the proportion of sleep-apnea patients classified as having a clinically significant PLMS index changed from 67% (under AASM rules) or 80% (under WASM/IRLSSG rules) down to 41% once movements tied to breathing events were excluded with a more precise, data-derived time window. Second, how the scoring is done matters too: in a separate obstructive-sleep-apnea cohort, automated AASM-rule scoring software significantly underestimated leg-movement counts compared with manual scoring by a human reader — especially in more severe apnea — even though manual AASM and manual WASM scoring by a human reader largely agreed with each other.

A single night's count is also unreliable on its own: research comparing two consecutive sleep-study nights in the same patients found the raw PLMS index swings substantially from one night to the next, while a related measure — how rhythmically clustered the movements are, not just how many there are — stayed far more stable. In practice, that means one night's PLMS number should be read as a rough estimate, not treated as a precise, unchanging severity score.

Periodic limb movements are not only a sleep-disruption issue. In a large prospective study of older men followed for over four years, a higher PLMS (and PLMS-with-arousal) index independently predicted a higher rate of newly diagnosed cardiovascular disease and roughly double the risk of newly diagnosed peripheral arterial disease — though it was not linked to newly diagnosed high blood pressure.

A meta-analysis pooling six studies found the same pattern in a different population mix: people with PLMS had significantly higher rates of coronary artery disease (odds ratio 1.57) and cardiovascular disease overall (odds ratio 1.28) compared with people without PLMS, although the specific odds of a heart attack were not significantly elevated.

The honest limit here matters: this is an association, not proof of cause and effect, and no clinical trial in this evidence base has tested whether deliberately reducing someone's PLMS count actually lowers their future cardiovascular risk — only that the two numbers move together in observational data. The meta-analysis's own authors called for that trial to be done.

Periodic limb movement treatment can effectively bring the movement count down — but reducing the count is not automatically the same thing as fixing sleep quality. A placebo-controlled trial in drug-naive RLS patients found that a single dose of a dopamine agonist (pramipexole) suppressed PLMS without improving the underlying instability in brain-wave arousal patterns during sleep, while clonazepam, a benzodiazepine, did the reverse — it calmed the arousal instability without reducing PLMS. Both drugs improved sensory RLS symptoms. That double dissociation shows the movement count and the sleep-disruption side of the picture can be targeted somewhat independently — one is not simply a symptom of the other.

For PLMD specifically, a small classic randomized trial compared four weeks of cognitive behavioral therapy against clonazepam in adults with PLMD and insomnia. The two approaches produced equivalent improvement on sleep-log measures and subjective sleep complaints, and cognitive behavioral therapy reduced daytime napping where clonazepam increased it — but clonazepam produced a larger reduction in the objective periodic-limb-movement-arousal count. In other words, a non-drug approach can rival medication on how sleep feels, without necessarily matching it on the raw movement number.

This page deliberately does not re-cover the RLS-specific medication landscape — iron repletion, alpha-2-delta ligands (gabapentin, pregabalin), and the augmentation risk that comes with long-term dopamine-agonist use — since that is covered in full, with its own evidence grading, on the long-term management plan and the page on why dopamine agonists stop working.

Any change to an existing PLMS, PLMD, or RLS medication — starting, stopping, or adjusting a dose — should happen only under a treating physician's supervision, and a dopamine agonist should never be stopped abruptly.

Because obstructive sleep apnea inflates PLMS counts under both major scoring systems (see "How periodic limb movements are diagnosed" above), a high PLMS index is not automatically a PLMD or RLS story on its own — comorbid, undiagnosed sleep apnea is a common confounder that needs to be identified and treated in its own right.

If snoring, witnessed pauses in breathing, gasping during sleep, or unexplained daytime sleepiness are also present, it is worth mentioning specifically to whoever orders the sleep study, so obstructive sleep apnea can be evaluated — and treated, for example with CPAP — alongside the periodic-limb-movement assessment rather than after it.